Core Viewpoint - Silvergate Bank misled investors regarding its customer vetting and anti-money laundering programs, leading to significant financial losses and the eventual bankruptcy of Silvergate Capital [1][2][3]. Group 1: Legal Settlement - A federal judge approved a $37.5 million cash settlement between investors and Silvergate Capital, resolving a securities fraud class action against the bank [2]. - The settlement is viewed as a favorable resolution for impacted investors, ensuring immediate recovery [4]. Group 2: Financial Impact - Investors claimed significant losses began in November 2022 as the truth about Silvergate's lax customer monitoring emerged [3]. - Following the collapse of FTX, Silvergate's deposits declined by $8.1 billion, representing a decrease of over 68% within three months [3]. - Silvergate was forced to sell illiquid securities at a loss exceeding $700 million and borrowed $4.3 billion from Federal Home Loan Banks to address liquidity issues [3]. Group 3: Regulatory Compliance - Silvergate Bank was subject to anti-terrorism and anti-money laundering regulations under the Bank Secrecy Act and the USA PATRIOT Act [4]. - Investors alleged that Silvergate failed to perform due diligence on clients using its Silvergate Exchange Network (SEN), which facilitated transactions among cryptocurrency platforms [5]. Group 4: Legal Proceedings - The case was originally filed on December 7, 2022, and the court appointed Cohen Milstein and Bernstein Litowitz as Lead Counsel on February 28, 2023 [3][6]. - Various public retirement systems and pension funds were appointed as Lead Plaintiffs in the case [6].

Core Viewpoint - Cohen Milstein Sellers & Toll PLLC is investigating GoHealth, Inc. for potential securities fraud related to a Medicare Advantage kickback scheme following a complaint from the Department of Justice [1][5]. Group 1: Investigation Details - The U.S. Department of Justice filed a False Claims Act complaint against GoHealth, alleging that from 2016 to at least 2021, the company and several insurers paid hundreds of millions of dollars in illegal kickbacks to brokers for enrollments in Medicare Advantage plans [5]. - Following the DOJ's lawsuit announcement, GoHealth's stock price dropped by $1.09 per share, or 10.35%, closing at $9.44 per share on May 1, 2025 [5]. Group 2: Investor Information - Investors who purchased shares of GoHealth between 2016 and May 1, 2025, are encouraged to contact Cohen Milstein for more information regarding the investigation [2]. - The law firm is actively seeking additional information and assistance related to the investigation [4]. Group 3: Law Firm Background - Cohen Milstein is recognized as one of the leading plaintiffs' law firms in the U.S., with a strong track record in securities litigation, having recovered billions for investors [7].

WASHINGTON, May 15, 2025 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC alerts investors that they have until June 16, 2025 to seek appointment as lead plaintiff in a securities class action lawsuit against Zenas BioPharma, Inc. (NASDAQ: ZBIO). The lawsuit, filed in the U.S. District Court for the District of Massachusetts, concerns alleged material misstatements in the company’s September 2024 IPO offering documents. [Click here for information about joining the class action] If you’d like to discu ...

WASHINGTON, D.C., May 13, 2025 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC issues the following update to investors in Zenas BioPharma, Inc. (NASDAQ: ZBIO) regarding the securities class action lawsuit filed in the U.S. District Court for the District of Massachusetts. Investors who purchased Zenas BioPharma shares pursuant and/or traceable to the company’s September 2024 initial public offering (IPO) have until June 16, 2025 to file a motion with the court to serve as lead plaintiff. [Click here ...

WASHINGTON, May 05, 2025 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC, a nationally recognized leader in investor protection, announces that investors who purchased shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO) in the company’s September 2024 initial public offering may seek to lead a federal securities class action. The deadline to move for appointment as lead plaintiff is June 16, 2025. [Click here for information about joining the class action] If you’d like to discuss this matter or your righ ...

WASHINGTON, D.C., May 01, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (NASDAQ: ZBIO) entered the public markets in September 2024 with a $17 per share debut and bold projections. But within weeks, investors were facing a much different picture—one that has now led to a securities class action lawsuit and an upcoming court deadline. Cohen Milstein Sellers & Toll PLLC, one of the nation’s top securities law firms, is calling on investors who purchased shares during the IPO to consider joining and seeking a ...

Core Viewpoint - Zenas BioPharma, Inc. is facing a securities class action lawsuit due to alleged misrepresentation of its financial condition during its September 2024 IPO, with a significant drop in stock value following the revelation of its actual funding capabilities [4]. Group 1: Lawsuit Details - The lawsuit was filed in the U.S. District Court for the District of Massachusetts, claiming that Zenas BioPharma overstated its operational funding period from 24 months to only 12 months [4]. - Following the disclosure of its true financial status, Zenas BioPharma's stock price fell nearly 49%, closing at $8.72 on April 15, 2025 [4]. - Investors who purchased shares during the IPO period are eligible to seek appointment as lead plaintiff, with a deadline set for June 16, 2025 [1]. Group 2: Role of Lead Plaintiff - The lead plaintiff will represent the class and guide the litigation strategy and settlement process, playing a significant role in overseeing the case [5]. - Any shareholder who purchased during the IPO can participate in recovery, but the lead plaintiff has a more active role [5]. Group 3: Cohen Milstein's Reputation - Cohen Milstein Sellers & Toll PLLC is recognized as a leading firm in securities fraud litigation, with over 100 attorneys across eight offices [6]. - The firm has a history of securing billions for investors, including a notable recovery of over $1 billion in the Wells Fargo Securities Litigation [7].

WASHINGTON, April 21, 2025 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC is investigating potential claims on behalf of investors who purchased securities of Zenas BioPharma, Inc. (NASDAQ:ZBIO) pursuant and/or traceable to the Company's September 2024 initial public offering ("IPO"). Investors who suffered significant losses are encouraged to contact the firm. [Click here for information about joining the class action] CASE OVERVIEW: Zenas BioPharma, a clinical-stage biopharmaceutical company, held ...

WASHINGTON, April 17, 2025 (GLOBE NEWSWIRE) -- Investors who lost money on securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) purchased pursuant and/or traceable to the Zenas BioPharma’s September 2024 initial public offering (the “IPO”) are encouraged to contact Cohen Milstein Sellers & Toll PLLC to learn about a recently filed securities class action lawsuit. [Click here for information about joining the class action] CASE BACKGROUND: Zenas BioPharma is a clinical-stage biopharmaceutical company developin ...